Literature DB >> 29250792

Increased acetylcholine and glutamate efflux in the prefrontal cortex following intranasal orexin-A (hypocretin-1).

Coleman B Calva1, Habiba Fayyaz1, Jim R Fadel1.   

Abstract

Orexin/hypocretin neurons of the lateral hypothalamus and perifornical area are integrators of physiological function. Previous work from our laboratory and others has shown the importance of orexin transmission in cognition. Age-related reductions in markers of orexin function further suggest that this neuropeptide may be a useful target for the treatment of age-related cognitive dysfunction. Intranasal administration of orexin-A (OxA) has shown promise as a therapeutic option for cognitive dysfunction. However, the neurochemical mechanisms of intranasal OxA administration are not fully understood. Here, we use immunohistochemistry and in vivo microdialysis to define the effects of acute intranasal OxA administration on: (i) activation of neuronal populations in the cortex, basal forebrain, and brainstem and (ii) acetylcholine (ACh) and glutamate efflux in the prefrontal cortex (PFC) of Fischer 344/Brown Norway F1 rats. Acute intranasal administration of OxA significantly increased c-Fos expression, a marker for neuronal activation, in the PFC and in subpopulations of basal forebrain cholinergic neurons. Subsequently, we investigated the effects of acute intranasal OxA on neurotransmitter efflux in the PFC and found that intranasal OxA significantly increased both ACh and glutamate efflux in this region. These findings were independent from any changes in c-Fos expression in orexin neurons, suggesting that these effects are not resultant from direct activation of orexin neurons. In total, these data indicate that intranasal OxA may enhance cognition through activation of distinct neuronal populations in the cortex and basal forebrain and through increased neurotransmission of ACh and glutamate in the PFC.
© 2017 International Society for Neurochemistry.

Entities:  

Keywords:  acetylcholine; cognition; hypocretin; intranasal; microdialysis; orexin

Mesh:

Substances:

Year:  2018        PMID: 29250792      PMCID: PMC5924451          DOI: 10.1111/jnc.14279

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  87 in total

1.  Age-related changes in hypocretin (orexin) immunoreactivity in the cat brainstem.

Authors:  Jian Hua Zhang; Sharon Sampogna; Francisco R Morales; Michael H Chase
Journal:  Brain Res       Date:  2002-03-15       Impact factor: 3.252

2.  Septohippocampal pathways contribute to system consolidation of a spatial memory: sequential implication of GABAergic and cholinergic neurons.

Authors:  Lucas Lecourtier; Anne Pereira de Vasconcelos; Elise Leroux; Brigitte Cosquer; Karin Geiger; Ségolène Lithfous; Jean-Christophe Cassel
Journal:  Hippocampus       Date:  2010-07-09       Impact factor: 3.899

Review 3.  Orexin receptors as therapeutic drug targets.

Authors:  Anthony L Gotter; Anthony J Roecker; Richard Hargreaves; Paul J Coleman; Christopher J Winrow; John J Renger
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

4.  Attention deficits in patients with narcolepsy.

Authors:  Martina Rieger; Geert Mayer; Siegfried Gauggel
Journal:  Sleep       Date:  2003-02-01       Impact factor: 5.849

5.  Age-related loss of orexin/hypocretin neurons.

Authors:  B A Kessler; E M Stanley; D Frederick-Duus; J Fadel
Journal:  Neuroscience       Date:  2011-01-22       Impact factor: 3.590

6.  Hypocretin (orexin) loss in Alzheimer's disease.

Authors:  Rolf Fronczek; Sarita van Geest; Marijke Frölich; Sebastiaan Overeem; Freek W C Roelandse; Gert Jan Lammers; Dick F Swaab
Journal:  Neurobiol Aging       Date:  2011-05-05       Impact factor: 4.673

Review 7.  Ventral pallidum roles in reward and motivation.

Authors:  Kyle S Smith; Amy J Tindell; J Wayne Aldridge; Kent C Berridge
Journal:  Behav Brain Res       Date:  2008-10-08       Impact factor: 3.332

8.  Food consumption and activity levels increase in rats following intranasal Hypocretin-1.

Authors:  Shyeilla V Dhuria; Jared M Fine; Deborah Bingham; Aleta L Svitak; Rachel B Burns; Amanda M Baillargeon; Scott S Panter; Abdul N Kazi; William H Frey; Leah R Hanson
Journal:  Neurosci Lett       Date:  2016-06-02       Impact factor: 3.046

9.  Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system.

Authors:  Shyeilla V Dhuria; Leah R Hanson; William H Frey
Journal:  J Pharm Sci       Date:  2009-07       Impact factor: 3.534

10.  Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep.

Authors:  Michihiro Mieda; Emi Hasegawa; Yaz Y Kisanuki; Christopher M Sinton; Masashi Yanagisawa; Takeshi Sakurai
Journal:  J Neurosci       Date:  2011-04-27       Impact factor: 6.167

View more
  9 in total

1.  Introduction to the Special Issue: "Making orexin-based therapies for addiction a reality: What are the steps from here?"

Authors:  Morgan H James; Gary Aston-Jones
Journal:  Brain Res       Date:  2020-01-10       Impact factor: 3.252

2.  Common pathways and communication between the brain and heart: connecting post-traumatic stress disorder and heart failure.

Authors:  Marlene A Wilson; Israel Liberzon; Merry L Lindsey; Yana Lokshina; Victoria B Risbrough; Renu Sah; Susan K Wood; John B Williamson; Francis G Spinale
Journal:  Stress       Date:  2019-06-04       Impact factor: 3.493

3.  Early Sociability and Social Memory Impairment in the A53T Mouse Model of Parkinson's Disease Are Ameliorated by Chemogenetic Modulation of Orexin Neuron Activity.

Authors:  Milos Stanojlovic; Jean Pierre Pallais Yllescas; Aarthi Vijayakumar; Catherine Kotz
Journal:  Mol Neurobiol       Date:  2019-06-27       Impact factor: 5.590

4.  Pyridostigmine bromide elicits progressive and chronic impairments in the cholinergic anti-inflammatory pathway in the prefrontal cortex and hippocampus of male rats.

Authors:  H E Burzynski; V A Macht; J L Woodruff; J N Crawford; J M Erichsen; G G Piroli; C A Grillo; J R Fadel; L P Reagan
Journal:  Neurobiol Stress       Date:  2022-04-15

Review 5.  Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction.

Authors:  Coleman B Calva; Jim R Fadel
Journal:  Brain Res       Date:  2018-08-24       Impact factor: 3.252

Review 6.  Intranasal insulin and orexins to treat age-related cognitive decline.

Authors:  Jennifer M Erichsen; Coleman B Calva; Lawrence P Reagan; Jim R Fadel
Journal:  Physiol Behav       Date:  2021-02-21

7.  Effects of Intranasal Orexin-A (Hypocretin-1) Administration on Neuronal Activation, Neurochemistry, and Attention in Aged Rats.

Authors:  Coleman B Calva; Habiba Fayyaz; Jim R Fadel
Journal:  Front Aging Neurosci       Date:  2020-01-22       Impact factor: 5.750

8.  Cholinergic neurotransmission in the basolateral amygdala during cued fear extinction.

Authors:  Devin M Kellis; Kris Ford Kaigler; Eric Witherspoon; Jim R Fadel; Marlene A Wilson
Journal:  Neurobiol Stress       Date:  2020-11-30

9.  Orexin (hypocretin) mediates light-dependent fluctuation of hippocampal function in a diurnal rodent.

Authors:  Joel E Soler; Hang Xiong; Faiez Samad; Fredric P Manfredsson; Alfred J Robison; Antonio A Núñez; Lily Yan
Journal:  Hippocampus       Date:  2021-07-15       Impact factor: 3.753

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.